From the Department of Pediatrics.
Section of Pediatric Infectious Diseases, Rush University Medical Center, Rush Medical College, Chicago, IL.
Pediatr Infect Dis J. 2019 May;38(5):490-495. doi: 10.1097/INF.0000000000002176.
Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae (KPC-CRE) are multidrug-resistant organisms causing morbidity and mortality worldwide. KPC-CRE prevalence is increasing in pediatric populations, though multi-centered data are lacking. Identifying risk factors for KPC-CRE infection in children and classifying genotypes is a priority in this vulnerable population.
A case-case-control study of patients (0-22 years) at 3 tertiary-care Chicago-area medical centers, 2008-2015, was conducted. Case group 1 children possessed KPC-CRE infections; case group 2 harbored carbapenem-susceptible Enterobacteriaceae (CSE) infections; controls had negative cultures. Case-control matching was 1:1:3 by age, infection site and hospital. Statistical and molecular analyses were performed.
Eighteen KPC-CRE infections were identified; median patient age was 16.5 years. Of 4 available KPC-CRE, 2 were unrelated, non-ST258 KP strains harboring blaKPC-2, one was a ST258 KP harboring blaKPC-3, and the last was an E. coli containing blaKPC-2. KPC-CRE and CSE-infected patients had more multidrug-resistant organisms infections, long-term care facility admissions and lengths of stay (LOS) > 7 days before culture. KPC-CRE and CSE patients had more gastrointestinal comorbidities (odds ratios [Ors], 28.0 and 6.4) and ≥ 3 comorbidities (Or 15.4 and 3.5) compared with controls; KPC-CRE patients had significantly more pulmonary and neurologic comorbidities (both ORs 4.4) or GI and pulmonary devices (ORs, 11.4 and 6.1). Compared with controls, CSE patients had more prior fluoroquinolone use (OR, 7.4); KPC-CRE patients had more carbapenem or aminoglycoside use (ORs, 10.0 and 8.0). Race, gender, LOS and mortality differences were insignificant.
Pediatric patients with KPC-CRE infection suffer from high multi-system disease/device burdens and exposures to carbapenems and aminoglycosides. Different from adult reports, non-ST258 KP strains were more common, and LOS and mortality rates were similar in all groups. Pediatric CRE control in should focus on modifiable risk factors including antibiotic and device utilization.
产碳青霉烯酶肺炎克雷伯菌(KPC)肠杆菌科(KPC-CRE)是一种具有多种耐药性的微生物,在全球范围内导致发病率和死亡率。儿科人群中 KPC-CRE 的流行率正在增加,尽管缺乏多中心数据。确定儿童 KPC-CRE 感染的危险因素并对基因型进行分类是这一脆弱人群的当务之急。
对 2008 年至 2015 年期间在芝加哥地区的 3 家三级医疗中心的患者(0-22 岁)进行了病例对照研究。病例组 1 患儿存在 KPC-CRE 感染;病例组 2 患儿存在碳青霉烯类药物敏感肠杆菌科(CSE)感染;对照组患儿的培养结果为阴性。病例对照的匹配是按照年龄、感染部位和医院进行的 1:1:3。进行了统计学和分子分析。
确定了 18 例 KPC-CRE 感染;中位患者年龄为 16.5 岁。在 4 例可获得的 KPC-CRE 中,有 2 例是不相关的非 ST258KP 菌株,携带 blaKPC-2,1 例是 ST258KP 菌株,携带 blaKPC-3,最后 1 例是含有 blaKPC-2 的大肠杆菌。KPC-CRE 和 CSE 感染患者在培养前有更多的多重耐药菌感染、长期护理机构入院和住院时间(LOS)>7 天。与对照组相比,KPC-CRE 和 CSE 患者的胃肠道合并症更多(比值比[ORs]分别为 28.0 和 6.4)和合并症≥3 种(ORs 分别为 15.4 和 3.5);KPC-CRE 患者的肺部和神经系统合并症明显更多(OR 均为 4.4)或胃肠道和肺部设备(ORs 分别为 11.4 和 6.1)。与对照组相比,CSE 患者有更多的氟喹诺酮类药物使用史(OR 为 7.4);KPC-CRE 患者有更多的碳青霉烯类或氨基糖苷类药物使用史(ORs 分别为 10.0 和 8.0)。种族、性别、LOS 和死亡率差异无统计学意义。
患有 KPC-CRE 感染的儿科患者患有多种系统疾病/设备负担,并且暴露于碳青霉烯类和氨基糖苷类药物中。与成人报告不同,非 ST258KP 菌株更为常见,所有组的 LOS 和死亡率相似。儿科 CRE 控制应侧重于可改变的危险因素,包括抗生素和设备的使用。